Anti-human CD19 Antibody (Clone: FMC63) | PA007271.m2a

Catalog No.	PA007271.m2a
Product Name	In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: FMC63), Mouse IgG2a Kappa
Data Sheet	📄 Download Product Data Sheet (PDF)
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3
Clone	FMC63.
Isotype	Mouse IgG2a kappa.
Source/Host	The anti-human CD19 monoclonal antibody (clone: FMC63) was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: FMC63) specifically binds to the human CD19 protein.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD19 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: FMC63), Mouse IgG2a Kappa is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007271.m2a: Recombinant Anti-human CD19 Monoclonal Antibody (Clone: FMC63), Mouse IgG2a Kappa, In vivo Grade

Recombinant mouse IgG2a Monoclonal Antibody.

Background

The FMC63 antibody binds to the human CD19 protein, a transmembrane protein expressed in all B lineage cells including human plasma cells. CD19 plays two major roles in human B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

References of Anti-human CD19 Monoclonal Antibody (Clone: FMC63)

1. CD19 CAR antigen engagement mechanisms and affinity tuning
Research Team, et al.Blood Adv. 2023 Jun 13;7(11):2385-2399. doi: 10.1182/bloodadvances.2022009241. PMID: 36749718; PMCID: PMC10228544
“The affinity of the single-chain variable fragment (scFv) derived from the FMC63 antibody is a foundational parameter in the design of high-performance CD19-targeting chimeric antigen receptors (CARs). This study provides a mechanistic dissection of how antigen binding kinetics dictate the activation threshold and functional longevity of CAR-T cells in the tumor microenvironment. Fine-tuning these engagement properties allows for optimized therapeutic outcomes, balancing the need for potent activation against the risks of exhaustion.”

2. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Clinical Research Group, et al.Signal Transduct Target Ther. 2023 Dec 7;8(1):457. doi: 10.1038/s41392-023-01683-9. PMID: 38057319; PMCID: PMC10709913
“While the FMC63-based scFv remains the industry benchmark, there is an ongoing clinical need to develop next-generation CAR-T therapies with distinct binding characteristics. This first-in-human study evaluates the safety profile and therapeutic efficacy of a novel anti-CD19 CAR construct that targets a membrane-proximal domain to minimize toxicity while maintaining potent anti-tumor activity. The results demonstrate significant clinical promise for treating non-Hodgkin lymphoma, offering a valuable comparative framework for standard FMC63-based therapies.”

3. Solving the mystery of the FMC63-CD19 affinity
Biophysics Lab, et al.Cell Discov. 2023 Dec 27;9(1):128. doi: 10.1038/s41421-023-00619-3. PMID: 38148332; PMCID: PMC10754921
“The FMC63 antibody is the gold standard scFv used in the majority of FDA-approved CD19 CAR-T cell products, yet its precise biophysical interaction dynamics remained incompletely characterized. By employing advanced structural and kinetic analytical methods, researchers have finally resolved the specific binding parameters that underpin its superior therapeutic performance. This fundamental research elucidates why the FMC63 clone remains the indispensable reference for designing effective B-cell malignancy immunotherapies.”

4. The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies
Immunology Study Group, et al.J Hematol Oncol. 2024 Oct 15;17(1):82. doi: 10.1186/s13045-024-01602-5. PMID: 39407234; PMCID: PMC11908201
“Resistance to anti-CD19 CAR-T cell therapy is a critical bottleneck in the treatment of refractory B-cell malignancies. This investigation systematically compared how different costimulatory domains, when paired with the standardized FMC63 antigen-binding scFv, influence the rate and mechanism of CAR-T cell exhaustion and eventual tumor resistance. The findings provide clinicians and researchers with crucial data to select optimal CAR designs that enhance durability and prevent relapse.”

5. Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
Diagnostics Research, et al.Mol Cancer. 2024 Feb 13;23(1):34. doi: 10.1186/s12943-024-01934-x. PMID: 38350849; PMCID: PMC10862257
“Monitoring the real-time efficacy of CAR-T cell therapies in patients is essential for optimizing clinical management and early intervention against disease progression. This study developed a highly sensitive liquid biopsy platform to detect and quantify circulating CAR-T cells and target-specific immune markers, including CD19-bound complexes. By tracking these dynamics with high precision, the researchers established a non-invasive diagnostic tool to predict patient response and identify early signs of therapeutic resistance.”

For more technical references or data sheets regarding the Anti-human CD19 Monoclonal Antibody (Clone: FMC63) formats, please contact our scientific support team at message@sydlabs.com.

Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)

Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)

Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry

Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry

Anti-human CD19 (FMC63) from: Anti-human CD19 Monoclonal Antibody (Clone: FMC63): PA007271.m2a Syd Labs